• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化脓性汗腺炎:一种针对古老疾病的新治疗方法。

Hidradenitis suppurativa: a new therapeutic approach for an old disease.

作者信息

Billewicz Marta, Wojtania Joanna, Woźniacka Anna

机构信息

Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland.

出版信息

Postepy Dermatol Alergol. 2024 Aug;41(4):350-356. doi: 10.5114/ada.2024.142185. Epub 2024 Aug 12.

DOI:10.5114/ada.2024.142185
PMID:39290899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11404097/
Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterised by recurrent painful nodules, abscesses, fistulas and scarring. The primary distinguishing factor in the complex, yet still not fully understood, pathogenesis is an inflammation occurring within the hair follicle, followed by an immune response leading to further development of the skin lesions seen in HS. The treatment of patients with HS is very difficult due to the complexity of the lesions and the frequent tendency to recurrence, which also has a negative impact on the psychological state of patients and directly translates into a reduced quality of life. This review article addresses the pathogenesis, clinical presentation of HS and, in particular, explores the new therapeutic options available.

摘要

化脓性汗腺炎(HS)是一种慢性炎症性疾病,其特征为反复发作的疼痛性结节、脓肿、瘘管和瘢痕形成。在其复杂但仍未完全理解的发病机制中,主要的区别因素是毛囊内发生的炎症,随后引发免疫反应,导致HS中所见皮肤病变的进一步发展。由于病变的复杂性和频繁复发的倾向,HS患者的治疗非常困难,这也对患者的心理状态产生负面影响,并直接导致生活质量下降。这篇综述文章阐述了HS的发病机制、临床表现,尤其探讨了现有的新治疗选择。

相似文献

1
Hidradenitis suppurativa: a new therapeutic approach for an old disease.化脓性汗腺炎:一种针对古老疾病的新治疗方法。
Postepy Dermatol Alergol. 2024 Aug;41(4):350-356. doi: 10.5114/ada.2024.142185. Epub 2024 Aug 12.
2
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。
Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.
3
New perspectives on the treatment of hidradenitis suppurativa.化脓性汗腺炎治疗的新视角。
Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920. doi: 10.1177/20406223211055920. eCollection 2021.
4
[Hidradenitis suppurativa/acne inversa: An update].[化脓性汗腺炎/反向性痤疮:最新进展]
Hautarzt. 2015 Jun;66(6):413-22. doi: 10.1007/s00105-015-3616-y.
5
S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version.S2k 指南治疗化脓性汗腺炎/反向痤疮 - 简化版。
J Dtsch Dermatol Ges. 2024 Jun;22(6):868-889. doi: 10.1111/ddg.15412. Epub 2024 May 21.
6
Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.基于欧洲化脓性汗腺炎指南的化脓性汗腺炎/反向性痤疮循证治疗方法
Rev Endocr Metab Disord. 2016 Sep;17(3):343-351. doi: 10.1007/s11154-016-9328-5.
7
Hidradenitis suppurativa: a review of current treatment options.化脓性汗腺炎:当前治疗选择综述
Int J Dermatol. 2022 Sep;61(9):1152-1164. doi: 10.1111/ijd.16115. Epub 2022 Feb 6.
8
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎:可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
9
Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution.重新思考化脓性汗腺炎的管理:对细菌相互作用和治疗进展的见解
Antibiotics (Basel). 2024 Mar 17;13(3):268. doi: 10.3390/antibiotics13030268.
10
[Acne inversa].[反向性痤疮]
Hautarzt. 2010 Jan;61(1):39-46. doi: 10.1007/s00105-009-1813-2.

本文引用的文献

1
Successful treatment of Hidradenitis Suppurativa with tofacitinib: two cases and a review of the literature.托法替布成功治疗化脓性汗腺炎:两例病例及文献综述
Oxf Med Case Reports. 2023 Mar 25;2023(3):omad003. doi: 10.1093/omcr/omad003. eCollection 2023 Mar.
2
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.司库奇尤单抗治疗中重度化脓性汗腺炎(SUNSHINE和SUNRISE研究):两项相同的多中心、随机、安慰剂对照、双盲3期试验的第16周和第52周结果
Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3.
3
Stress signalling and STAT1 activation characterize the keratinocytic gene expression pattern in Hidradenitis suppurativa.压力信号和 STAT1 激活是化脓性汗腺炎角质形成细胞基因表达模式的特征。
J Eur Acad Dermatol Venereol. 2022 Dec;36(12):2488-2498. doi: 10.1111/jdv.18465. Epub 2022 Aug 9.
4
Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?'.意大利南部一家转诊中心为减少阿达木单抗停药所采取的策略:对“我们能否延长化脓性汗腺炎生物治疗的药物存活时间?”的评论
Clin Exp Dermatol. 2022 Oct;47(10):1864-1865. doi: 10.1111/ced.15291. Epub 2022 Jul 12.
5
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.比美吉珠单抗治疗中重度化脓性汗腺炎的疗效和安全性:一项 2 期、双盲、安慰剂对照随机临床试验。
JAMA Dermatol. 2021 Nov 1;157(11):1279-1288. doi: 10.1001/jamadermatol.2021.2905.
6
The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study.四环素类药物和克林霉素联合利福平治疗化脓性汗腺炎的疗效和耐受性:一项前瞻性欧洲队列研究的结果。
J Am Acad Dermatol. 2021 Aug;85(2):369-378. doi: 10.1016/j.jaad.2020.12.089. Epub 2021 Jan 20.
7
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside.IL-23/IL-17 通路在炎症性皮肤病中的作用:从基础到临床。
Front Immunol. 2020 Nov 17;11:594735. doi: 10.3389/fimmu.2020.594735. eCollection 2020.
8
Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa.高剂量皮损内曲安奈德治疗化脓性汗腺炎的疗效。
Int J Dermatol. 2021 Feb;60(2):217-221. doi: 10.1111/ijd.15124. Epub 2020 Aug 17.
9
Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-to-moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance.15%外用间苯二酚作为轻度至中度化脓性汗腺炎长期治疗的疗效和安全性:在抗生素耐药背景下,是克林霉素的有效替代方案。
Br J Dermatol. 2020 Dec;183(6):1117-1119. doi: 10.1111/bjd.19337. Epub 2020 Aug 9.
10
Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases).司库奇尤单抗治疗化脓性汗腺炎的有效性:一项开放性研究(20例)。
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e750-e751. doi: 10.1111/jdv.16605. Epub 2020 Jun 8.